Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 13/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.36 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2400367 | 0.86 | NR3C2 (0.41) | KIF11KDR | |
| SCHEMBL15157445 | 0.80 | KIF11 (0.50) | KIF11KDM1AKCNN4 | |
| SCHEMBL3161665 | 0.79 | PLA2G7 (0.49) | KCNN4CES2 | |
| SCHEMBL16649740 | 0.78 | KIF11 (0.44) | KIF11KDM1A | |
| SCHEMBL29438427 | 0.77 | KIF11 (0.73) | KIF11KDM1A | |
| SCHEMBL48409 | 0.77 | KIF11 (0.73) | KIF11KDM1A | |
| SCHEMBL16649910 | 0.77 | KIF11 (0.47) | KIF11KDM1A | |
| SCHEMBL16649704 | 0.77 | KIF11 (0.47) | KIF11KDM1AKDRKCNQ3KCNQ2 | |
| SCHEMBL20740835 | 0.77 | KIF11 (0.56) | KIF11KDM1A | |
| SCHEMBL585211 | 0.76 | KDM4E (0.50) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | claimed |
| EP-2121617-B1 | CB1 RECEPTOR MODULATORS | 7TM PHARMA AS (DK) | 2014-01-22 | — | — | EP | disclosed |
| US-20100010061-A1 | CB1 RECEPTOR MODULATORS | 7TM PHARMA A/S (DK) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010061-A1 | CB1 RECEPTOR MODULATORS | CNR1, CNR2, GPR6 | KIF11 3251/4885KDM1A 3600/4885KCNN4 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.